BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel’s largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine.

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Size: 540 KB